HomeCompareBAX vs MCHP

BAX vs MCHP: Dividend Comparison 2026

BAX yields 2.28% · MCHP yields 3.03%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCHP wins by $436.16M in total portfolio value
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
MCHP
MCHP
● Live price
3.03%
Share price
$60.06
Annual div
$1.82
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$436.18M
Annual income
$410,174,962.43
Full MCHP calculator →

Portfolio growth — BAX vs MCHP

📍 MCHP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXMCHP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + MCHP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
MCHP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
MCHP
Annual income on $10K today (after 15% tax)
$257.58/yr
After 10yr DRIP, annual income (after tax)
$348,648,718.07/yr
At 15% tax rate, MCHP beats the other by $348,648,709.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + MCHP for your $10,000?

BAX: 50%MCHP: 50%
100% MCHP50/50100% BAX
Portfolio after 10yr
$218.10M
Annual income
$205,087,486.34/yr
Blended yield
94.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCHP right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
MCHP
Analyst Ratings
2
Strong
30
Buy
14
Hold
Consensus: Buy
Price Target
$87.00
+44.9% upside vs current
Range: $69.00 — $100.00
Altman Z
3.5
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
MCHP buys
0
No recent congressional trades found for BAX or MCHP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXMCHP
Forward yield2.28%3.03%
Annual dividend / share$0.36$1.82
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%100%
Portfolio after 10y$20.6K$436.18M
Annual income after 10y$10.26$410,174,962.43
Total dividends collected$602.00$434.25M
Payment frequencyquarterlyquarterly
SectorHealthcareTechnology
Analyst consensusHoldBuy
Analyst price target$19.75$87.00

Year-by-year: BAX vs MCHP ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrMCHP PortfolioMCHP Income/yrGap
1← crossover$10,866$166.33$11,306$606.06$440.00MCHP
2$11,750$123.31$13,378$1,280.78$1.6KMCHP
3$12,664$90.97$17,147$2,832.75$4.5KMCHP
4$13,617$66.89$25,134$6,786.65$11.5KMCHP
5$14,619$49.07$45,488$18,593.90$30.9KMCHP
6$15,679$35.94$111,571$62,898.72$95.9KMCHP
7$16,802$26.30$407,746$288,365.50$390.9KMCHP
8$17,998$19.23$2,406,121$1,969,832.89$2.39MMCHP
9$19,272$14.05$24,301,727$21,727,176.85$24.28MMCHP
10$20,631$10.26$436,177,810$410,174,962.43$436.16MMCHP

BAX vs MCHP: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

MCHPTechnology

Microchip Technology Incorporated develops, manufactures, and sells smart, connected, and secure embedded control solutions in the Americas, Europe, and Asia. The company offers general purpose 8-bit, 16-bit, and 32-bit microcontrollers; 32-bit embedded microprocessors markets; and specialized microcontrollers for automotive, industrial, computing, communications, lighting, power supplies, motor control, human machine interface, security, wired connectivity, and wireless connectivity applications. It also provides development tools that enable system designers to program microcontroller and microprocessor products for specific applications; field-programmable gate array (FPGA) products; and analog, interface, mixed signal, and timing products comprising power management, linear, mixed-signal, high-voltage, thermal management, discrete diodes and metal oxide semiconductor field effect transistors (MOSFETS), radio frequency (RF), drivers, safety, security, timing, USB, Ethernet, wireless, and other interface products. In addition, the company offers memory products consisting of serial electrically erasable programmable read-only memory, serial flash memories, parallel flash memories, serial static random access memories, and serial electrically erasable random access memories for the production of very small footprint devices; and licenses its SuperFlash embedded flash and NVM technologies to foundries, integrated device manufacturers, and design partners for use in the manufacture of microcontroller products, gate array, RF, analog, and neuromorphic compute products that require embedded non-volatile memory, as well as provides engineering services. Further, it offers wafer foundry and assembly, and test subcontracting manufacturing services; and timing systems products, application specific integrated circuits, and aerospace products. Microchip Technology Incorporated was incorporated in 1989 and is headquartered in Chandler, Arizona.

Full MCHP Calculator →
📬

Get this BAX vs MCHP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.